Jacobs Solutions Inc. Stock Falls 4.1%, Underperforms Peers
Dow Jones2026/09/24 20:35This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Jacobs Solutions Inc. slipped 4.1% to $135.33 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining mostly unchanged at 7,704.13 and the Dow Jones Industrial Average falling 0.3% to 51,349.98.
This was the stock's third consecutive day of losses.
Jacobs Solutions Inc. closed 19.7% below its 52-week high of $168.44, which the company reached on October 24th.
The stock underperformed when compared to some of its peers, as General Dynamics Corp. fell 2.1% to $336.29, Quanta Services Inc. rose 1.4% to $643.50, and Leidos Holdings Inc. fell 1.07% to $123.35.
Trading volume totaled 792,737, compared to the 50-day average of 846,292.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 24, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish